Last reviewed · How we verify
IMA203 product- flat dose — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
IMA203 product- flat dose (IMA203 product- flat dose) — Immatics US, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| IMA203 product- flat dose TARGET | IMA203 product- flat dose | Immatics US, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- IMA203 product- flat dose CI watch — RSS
- IMA203 product- flat dose CI watch — Atom
- IMA203 product- flat dose CI watch — JSON
- IMA203 product- flat dose alone — RSS
Cite this brief
Drug Landscape (2026). IMA203 product- flat dose — Competitive Intelligence Brief. https://druglandscape.com/ci/ima203-product-flat-dose. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing